2269N Stock Chart & Stats
$66.00
$0.00(0.00%)
At close: 4:00 PM EDT
$66.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$66.00 - $66.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$354.57B
Enterprise Value$123.38K
Total Cash (Recent Filing)$15.74B
Total Debt (Recent Filing)$3.11B
Price to Earnings (P/E)28.0
Beta0.00
Next Earnings
Aug 25, 2026EPS Estimate
1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.19
Shares Outstanding4,143,562,500
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)2.53
Price to Sales (P/S)5.48
P/FCF Ratio42.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$111.80Price Target Upside69.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)2.83
Revenue Forecast (FY)$56.22B
Bulls Say, Bears Say
Bulls Say
Strong ProfitabilityHigh 2025 gross, EBIT and net margins signal durable earnings power from the core biologics services. Robust margins provide pricing flexibility, internal funding for capex or R&D, and a buffer against cyclical demand swings, supporting long-term reinvestment.
Conservative Balance SheetLow and falling leverage plus solid ROE give the company financial flexibility to fund capacity expansion or absorb shocks without heavy refinancing. A conservative balance sheet reduces solvency risk and supports strategic investments over the medium term.
Integrated CRDMO PlatformAn end-to-end service offering creates a structural competitive advantage: clients can consolidate vendors, programs that advance to later stages generate recurring manufacturing revenue, and cross-selling across services increases customer stickiness and lifetime value.
Bears Say
Slowing Revenue GrowthThe pronounced deceleration in top-line expansion constrains the company’s ability to lift facility utilization and spread fixed costs. Without renewed contract wins or pipeline progression, slower revenue undermines margin leverage and long-term cash generation potential.
Weak Cash ConversionAlthough FCF improved in 2025, conversion remains well below earnings and past years showed negative FCF, reflecting volatility from investment and working capital. Persistent weak conversion can limit self-funding for capacity additions and raise reliance on external capital.
Margins Below Prior PeaksCurrent margins, while healthy, are below earlier peak levels, suggesting normalization or cost/mix pressure. If competitive pricing, higher input costs, or underutilized capacity persist, sustaining past peak profitability will be difficult and could cap future returns.
Wuxi Biologics (Cayman) News
2269N FAQ
What was Wuxi Biologics (Cayman) Inc.’s price range in the past 12 months?
Wuxi Biologics (Cayman) Inc. lowest stock price was $66.00 and its highest was $66.00 in the past 12 months.
What is Wuxi Biologics (Cayman) Inc.’s market cap?
Wuxi Biologics (Cayman) Inc.’s market cap is $354.57B.
When is Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date?
Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date is Aug 25, 2026 which is in 22 days.
How were Wuxi Biologics (Cayman) Inc.’s earnings last quarter?
Wuxi Biologics (Cayman) Inc. released its earnings results on Mar 24, 2026. The company reported $1.502 earnings per share for the quarter, missing the consensus estimate of $1.616 by -$0.114.
Is Wuxi Biologics (Cayman) Inc. overvalued?
According to Wall Street analysts Wuxi Biologics (Cayman) Inc.’s price is currently Undervalued.
Does Wuxi Biologics (Cayman) Inc. pay dividends?
Wuxi Biologics (Cayman) Inc. does not currently pay dividends.
What is Wuxi Biologics (Cayman) Inc.’s EPS estimate?
Wuxi Biologics (Cayman) Inc.’s EPS estimate is 1.15.
How many shares outstanding does Wuxi Biologics (Cayman) Inc. have?
Wuxi Biologics (Cayman) Inc. has 4,143,562,500 shares outstanding.
What happened to Wuxi Biologics (Cayman) Inc.’s price movement after its last earnings report?
Wuxi Biologics (Cayman) Inc. reported an EPS of $1.502 in its last earnings report, missing expectations of $1.616. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) Inc.?
Currently, no hedge funds are holding shares in MX:2269N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Wuxi Biologics (Cayman) Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
16.77%
Trailing 12-Months
Company Description
Wuxi Biologics (Cayman) Inc.
Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturing. The company's operations have a global footprint, serving clients across the People's Republic of China, North America, Europe, and other international regions. Its diversified offerings also include specialized consultation in biopharmaceutical technology, international sales contracting, the development and deployment of advanced testing methodologies, and robust marketing and sales support. Furthermore, WuXi Biologics is involved in providing dedicated biologics clinical and manufacturing services, the production and distribution of various medical products, contract development and manufacturing (CDMO) for vaccines and associated businesses, and acting as a supplier of key materials. The firm maintains strategic partnerships with notable entities such as ImmuneOncia Therapeutics, Legochem Biosciences Inc., Worg Pharma, OncoC4, and Exelixis Inc.
2269N Company Deck
2269N Earnings Call
Q4 2026
0:00 / 0:00
2269N Stock 12 Month Forecast
Average Price Target
$111.80
▲(69.40% Upside)